{"nctId":"NCT00891371","briefTitle":"Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea","startDateStruct":{"date":"2009-07"},"conditions":["Diarrhea"],"count":42,"armGroups":[{"label":"lanreotide (Autogel formulation) Autogel 120mg","type":"EXPERIMENTAL","interventionNames":["Drug: lanreotide (Autogel formulation)"]}],"interventions":[{"name":"lanreotide (Autogel formulation)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male/female with refractory diarrhea for at least 1 month, after normal extended work-up to exclude causes of diarrhea, not or not enough responding to standard anti-diuretics as evaluated by the investigator\n* Patient mentally fit for completing a diary\n\nExclusion Criteria:\n\n* Has already received a treatment with somatostatin analogues for the treatment of refractory diarrhea\n* Had a weight of stool \\< 600g in a 72hrs stool collection\n* Has received a treatment with laxatives within the last week before study entry\n* Suffers from IBS with alternating bowel habits and predominant constipation, suffers from infectious and/or inflammatory gastro-enteritis (colitis ulcerosa, crohn's disease and macroscopic colitis)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients Having Minimum Reduction of 50% or Normalization (≤3 Stools/24hours) in the Mean Number of Stools (Mean of Last 7 Days)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in QOL-Quality of Life {Assess Using Short Form (SF-36) and Irritable Bowel Syndrome (IBS)-QOL} Compared to Baseline","description":"SF36 QOL includes 1 multi-item scale measuring each of 8 health concepts. These scores are summed to produce raw scale scores for each health concept which are transformed to a 0-100 scale. The lower the score the more disability. The higher the score the less disability. There is in addition a single-item measure of Health Transition\n\nIBS-QOL is a self-report QOL measure specific to IBS that can be used to assess impact of IBS and its treatment. This consists of 34 items,each with a 5 point response scale.Individual responses to 34 items are summed and averaged for a total score and transformed to a 0-100 scale with higher scores indicating better IBS specific QOL","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"20.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"19.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"18.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"23.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"19.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":"21.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"28.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":"23.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"34.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"40.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":"35.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"39.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"22.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"22.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"24.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"23.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"27.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":"28.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":"27.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"27.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":"27.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":"29.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.3","spread":"34.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":"31.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":"31.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":"28.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":"29.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"30.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"16.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"16.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"19.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"19.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":"21.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.9","spread":"22.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":"22.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":"22.5"}]}]}]},{"type":"SECONDARY","title":"Change in Median Score of Stool Consistency (Bristol Stool Form Scale) Compared to Baseline","description":"Each patient scored his/her stool on the Bristol Stool Form Scale: Type 1 - Separate hard lumps, like nuts (hard to pass); Type 2 - Sausage-shaped but lumpy; Type 3 - Like a sausage but with cracks on its surface; Type 4 - Like a sausage or snake, smooth and soft; Type 5 - Soft blobs with clear-cut edges (passed easily); Type 6 - Fluffy pieces with ragged edges, a mushy stool; Type 7 - Water no solid pieces, Entirely liquid","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Mean Number of Stools Compared to Baseline","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.9","spread":"36.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.7","spread":"38.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Relative Frequency of Normalization (≤3 Stools) in Subjects","description":"Normalization of stool frequency in subjects with refractory diarrhoea at Day 28 and Day 56 (mean of last 7 days) compared to Baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.5","spread":"34.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.0","spread":"34.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Having Minimum Reduction of At Least 50% or Normalization of the Mean Number of Stools","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":36},"commonTop":["Abdominal pain","Nausea","Fatigue","Headache","Injection site nodule"]}}}